


## Accepted Manuscript

Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial

Cary O. Harding, R. Stephen Amato, Mary Stuy, Nicola Longo, Barbara K. Burton, John Posner, Haoling H. Weng, Markus Merilainen, Zhonghua Gu, Joy Jiang, Jerry Vockley, PRISM-2 Investigators



PII: S1096-7192(18)30020-9  
DOI: doi:[10.1016/j.ymgme.2018.03.003](https://doi.org/10.1016/j.ymgme.2018.03.003)  
Reference: YMGME 6329

To appear in: *Molecular Genetics and Metabolism*

Received date: 14 January 2018  
Revised date: 11 March 2018  
Accepted date: 12 March 2018

Please cite this article as: Cary O. Harding, R. Stephen Amato, Mary Stuy, Nicola Longo, Barbara K. Burton, John Posner, Haoling H. Weng, Markus Merilainen, Zhonghua Gu, Joy Jiang, Jerry Vockley, PRISM-2 Investigators, Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. *Ymgme*(2018), doi:[10.1016/j.ymgme.2018.03.003](https://doi.org/10.1016/j.ymgme.2018.03.003)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation Phase 3 clinical trial**

Cary O. Harding, MD<sup>a\*</sup>, R. Stephen Amato, MD, PhD<sup>b</sup>, Mary Stuy, MD<sup>c</sup>, Nicola Longo, MD, PhD<sup>d</sup>, Barbara K. Burton, MD<sup>e</sup>, John Posner, MBBS, PhD<sup>f</sup>, Haoling H. Weng, MD, MHS<sup>g</sup>, Markus Merilainen, MD<sup>g</sup>, Zhonghua Gu, PhD<sup>g</sup>, Joy Jiang, PharmD<sup>g</sup>, Jerry Vockley, MD, PhD<sup>h</sup>, on behalf of the PRISM-2 Investigators

<sup>a</sup> Molecular and Medical Genetics, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA; hardingc@ohsu.edu

<sup>b</sup> Medical Genetics and Metabolism, University of Kentucky, 138 Leader Avenue, #119-130, Lexington, KY, 40506, USA; stephen.amato@uky.edu

<sup>c</sup> Department of Medical and Molecular Genetics, Indiana University, 975 W Walnut St, Research and Library Building IB 130, Indianapolis, IN, 46202, USA; mstuy@iu.edu

<sup>d</sup> Department of Pediatrics, Division of Medical Genetics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA; Nicola.Longo@hsc.utah.edu

<sup>e</sup> Department of Pediatrics, Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL, 60601, USA; bburton@luriechildrens.org

<sup>f</sup> Department of Life Sciences and Medicine, King's College London Strand, Franklin Wilkins Building, Stamford Street, London, UK; john.posner@talk21.com

<sup>g</sup> BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA, 94949, USA; holly.weng@bmrn.com; mmerilainen@bmrn.com; kgu@bmrn.com; joy.jiang@bmrn.com

<sup>h</sup> Department of Pediatrics, Division of Medical Genetics, University of Pittsburgh and Children's Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, PA, 15224, USA; vockleyg@upmc.edu

Download English Version:

<https://daneshyari.com/en/article/8342980>

Download Persian Version:

<https://daneshyari.com/article/8342980>

[Daneshyari.com](https://daneshyari.com)